461 related articles for article (PubMed ID: 9610871)
1. Combined treatment of stage IV melanoma patients with amifostine and fotemustine--a pilot study.
Mohr P; Makki A; Breitbart E; Schadendorf D
Melanoma Res; 1998 Apr; 8(2):166-9. PubMed ID: 9610871
[TBL] [Abstract][Full Text] [Related]
2. Fotemustine in the treatment of brain primary tumors and metastases.
Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma.
Chang J; Atkinson H; A'Hern R; Lorentzos A; Gore ME
Eur J Cancer; 1994; 30A(14):2093-5. PubMed ID: 7857710
[TBL] [Abstract][Full Text] [Related]
4. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.
Di Giacomo AM; Ascierto PA; Pilla L; Santinami M; Ferrucci PF; Giannarelli D; Marasco A; Rivoltini L; Simeone E; Nicoletti SV; Fonsatti E; Annesi D; Queirolo P; Testori A; Ridolfi R; Parmiani G; Maio M
Lancet Oncol; 2012 Sep; 13(9):879-86. PubMed ID: 22894884
[TBL] [Abstract][Full Text] [Related]
5. Fotemustine plus dacarbazine for malignant melanoma.
Avril MF; Bonneterre J; Cupissol D; Grob JJ; Kalis B; Fumoleau P; Kerbrat P; Israel L; Fargeot P; Lambert D
Eur J Cancer; 1992; 28A(11):1807-11. PubMed ID: 1389514
[TBL] [Abstract][Full Text] [Related]
6. Fotemustine plus dacarbazine in advanced stage III malignant melanoma.
Binder M; Winkler A; Dorffner R; Glebowski E; Wolff K; Pehamberger H
Eur J Cancer; 1992; 28A(11):1814-6. PubMed ID: 1389516
[TBL] [Abstract][Full Text] [Related]
7. Persistent thrombocytopenia during melanoma treatment with fotemustine.
Turrisi G; Sozzi P; Marinozzi C; Clerico MA
Melanoma Res; 2006 Dec; 16(6):543-4. PubMed ID: 17119456
[TBL] [Abstract][Full Text] [Related]
8. Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases.
Di Giacomo AM; Chiarion-Sileni V; Del Vecchio M; Ferrucci PF; Guida M; Quaglino P; Guidoboni M; Marchetti P; Cutaia O; Amato G; Covre A; Camerini R; Calabrò L; Valente M; Giannarelli D; Mandalà M; Maio M
Clin Cancer Res; 2021 Sep; 27(17):4737-4745. PubMed ID: 34112708
[TBL] [Abstract][Full Text] [Related]
9. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group.
Avril MF; Bonneterre J; Delaunay M; Grosshans E; Fumoleua P; Israel L; Bugat R; Namer M; Cupissol D; Kerbrat P
Cancer Chemother Pharmacol; 1990; 27(2):81-4. PubMed ID: 2249337
[TBL] [Abstract][Full Text] [Related]
11. Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma.
Richard MA; Grob JJ; Zarrour H; Bassères N; Bizzari JP; Gérard B; Bonerandi JJ
Melanoma Res; 1998 Apr; 8(2):170-4. PubMed ID: 9610872
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.
Del Vecchio M; Mortarini R; Canova S; Di Guardo L; Pimpinelli N; Sertoli MR; Bedognetti D; Queirolo P; Morosini P; Perrone T; Bajetta E; Anichini A
Clin Cancer Res; 2010 Dec; 16(23):5862-72. PubMed ID: 21030496
[TBL] [Abstract][Full Text] [Related]
13. Positive phase II study in the treatment of advanced malignant melanoma with fotemustine.
Schallreuter KU; Wenzel E; Brassow FW; Berger J; Breitbart EW; Teichmann W
Cancer Chemother Pharmacol; 1991; 29(1):85-7. PubMed ID: 1742855
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma.
Jacquillat C; Khayat D; Banzet P; Weil M; Avril MF; Fumoleau P; Namer M; Bonneterre J; Kerbrat P; Bonerandi JJ
Cancer Chemother Pharmacol; 1990; 25(4):263-6. PubMed ID: 2403853
[TBL] [Abstract][Full Text] [Related]
15. Sequential interferon-alpha2b, interleukin-2 and fotemustine for patients with metastatic melanoma.
Terheyden P; Becker JC; Kämpgen E; Bröcker EB
Melanoma Res; 2000 Oct; 10(5):475-82. PubMed ID: 11095409
[TBL] [Abstract][Full Text] [Related]
16. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
Ridolfi L; Fiorentini G; Guida M; Michiara M; Freschi A; Aitini E; Ballardini M; Bichisao E; Ridolfi R;
Melanoma Res; 2009 Apr; 19(2):100-5. PubMed ID: 19262411
[TBL] [Abstract][Full Text] [Related]
17. Fotemustine and interferon alpha2b in metastatic malignant melanoma.
Weichenthal M; Mohr P; Stephan U; Altenhoff J; Kowalzick L; Marseille A; Sarkany M; Hossfeld DK; Breitbart EW
J Cancer Res Clin Oncol; 1998 Jan; 124(1):55-9. PubMed ID: 9498836
[TBL] [Abstract][Full Text] [Related]
18. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.
Di Giacomo AM; Ascierto PA; Queirolo P; Pilla L; Ridolfi R; Santinami M; Testori A; Simeone E; Guidoboni M; Maurichi A; Orgiano L; Spadola G; Del Vecchio M; Danielli R; Calabrò L; Annesi D; Giannarelli D; Maccalli C; Fonsatti E; Parmiani G; Maio M
Ann Oncol; 2015 Apr; 26(4):798-803. PubMed ID: 25538176
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide in combination with fotemustine in patients with metastatic melanoma.
Tas F; Camlica H; Topuz E
Cancer Chemother Pharmacol; 2008 Jul; 62(2):293-8. PubMed ID: 17909803
[TBL] [Abstract][Full Text] [Related]
20. Fotemustine--an advance in the treatment of metastatic malignant melanoma.
Merimsky O; Inbar M; Gerard B; Chaitchik S
Melanoma Res; 1992 Dec; 2(5-6):401-6. PubMed ID: 1292787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]